Holen Sie sich die Stockscreener-App
4.01
0.25%
0.010
Handel nachbörslich:
4.08
0.07
+1.75%
Verastem Inc Aktie (VSTM) Neueste Nachrichten
Early data on new KRAS cancer pill to be detailed June 23 - Stock Titan
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM) - The Globe and Mail
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits
VSTM Technical Analysis & Stock Price Forecast - Intellectia AI
Verastem’s VS-7375 receives FDA fast track status for lung cancer - Investing.com UK
Verastem announces FDA Fast Track designation for VS-7375 - TipRanks
Verastem, Inc. receives U.S. FDA fast track for KRAS G12D inhibitor in NSCLC treatment - Traders Union
Verastem (VSTM) Surges 11% Following FDA Fast Track Designation - GuruFocus
Verastem’s VS-7375 receives FDA fast track status for lung cancer By Investing.com - Investing.com South Africa
Verastem (VSTM) Receives Fast Track Designation for Cancer Treat - GuruFocus
Verastem stock rises on FDA fast track for lung cancer drug - Investing.com Canada
Verastem Initiates Phase 2 Target-D 202 Trial For Advanced NSCLC - TradingView
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung - Business Wire
Verastem Inc stock (US92335V1008): Nasdaq-listed oncology player steadies around late-May levels - AD HOC NEWS
VSTM Stock Price, Quote & Chart | VERASTEM INC (NASDAQ:VSTM) - ChartMill
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Verastem (VSTM) Declines 2.5% as Biotech Sector Headwinds PersistPullback Trade - thelegaladvocate.com
Verastem (NASDAQ: VSTM) director receives 108,000 restricted stock units - Stock Titan
New Verastem (NASDAQ: VSTM) director files initial Form 3 ownership - Stock Titan
[144] Verastem, Inc. SEC Filing - Stock Titan
Biopharma Verastem Oncology joins Jefferies healthcare fireside chat June 3 - Stock Titan
Verastem Oncology to Present at Jefferies Healthcare Conference - marketscreener.com
Verastem: Robert Gagnon Stepped Down From Board Following End of Term on May 21 >VSTM - Moomoo
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Director at Verastem (VSTM) receives 36,000 RSUs as equity award - Stock Titan
Director Brian Stuglik (VSTM) awarded 36,000 Verastem RSUs with 2026–2027 vesting - Stock Titan
Verastem (NASDAQ: VSTM) awards 36,000 RSUs to director Rowinsky - Stock Titan
Verastem (VSTM) director Michelle Robertson awarded 36,000 RSUs - Stock Titan
Verastem (VSTM) director Anil Kapur receives 36,000 RSU equity award - Stock Titan
Verastem (VSTM) director awarded 36,000 RSUs vesting through 2027 - Stock Titan
Verastem (VSTM) director gets 36,000 RSU award vesting through 2027 - Stock Titan
Verastem Oncology Appoints Michael P. Bailey to Board of Directo - GuruFocus
Verastem (VSTM) stockholders back board slate, equity plans and auditor at 2026 meeting - Stock Titan
Verastem Oncology appoints Michael Bailey to board By Investing.com - Investing.com Australia
Verastem Oncology appoints Michael Bailey to board - Investing.com
AVEO CEO Michael Bailey joins Verastem board, rare cancer focus - Stock Titan
Verastem Q1 2026 Earnings: Narrower-than-Expected Loss Beats Estimates; Stock Edges HigherEnergy Earnings Report - thelegaladvocate.com
Verastem (VSTM) Q1 2026 Earnings: Why the Beat MattersEarnings Seasonality - thelegaladvocate.com
Verastem Q1 earnings call highlights - MSN
Verastem Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Cancer Stocks That Are Advancing the Future of Oncology Care - TradingView
Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Verastem Q3 2025 Earnings Preview - MSN
Foresite (VSTM) holds 3,146,631 shares, reporting 3.6% stake - Stock Titan
Armistice Capital 5.23% stake in Verastem (VSTM) via managed fund - Stock Titan
RTW Funds, Roderick Wong Report 9.99% of Verastem (VSTM) - Stock Titan
Balyasny-affiliated holders report 1.36M shares in Verastem (VSTM) - Stock Titan
Verastem Oncology announces management changes - MSN
VSTM Maintained by Mizuho -- Price Target Lowered to $14.00 - GuruFocus
MSN Money - MSN
Mizuho Adjusts Price Target on Verastem to $14 From $16, Maintains Outperform Rating - Moomoo
Verastem, Inc. drives patient-focused efforts in rare ovarian cancer awareness - Traders Union
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14 - Moomoo
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):